Gene injection aims to restore vision in inherited blindness trial
NCT ID NCT07054632
Summary
This study is testing whether a one-time gene therapy injection (called LX101) can improve vision in people with a specific inherited retinal disease that causes blindness. The trial involves 30 participants, aged 6 and older, who have vision loss due to mutations in the RPE65 gene. Participants are randomly assigned to either receive the gene therapy injection or no treatment, so researchers can compare outcomes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INHERITED RETINAL DYSTROPHY ASSOCIATED WITH RPE65 MUTATIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai General Hospital
Shanghai, China
-
Southwest Hospital of AMU
Chongqing, China
-
Tianjin Medical University Ophthalmology Hospital
Tianjin, China
-
Zhongshan Ophthalmic Center, Sun Yat sen University
Guangzhou, Guangdong, China
Conditions
Explore the condition pages connected to this study.